Audentes Therapeutics, Inc
BOLD
BOLD was delisted on the 14th of January, 2020.
123 hedge funds and large institutions have $1.37B invested in Audentes Therapeutics, Inc in 2018 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 52 increasing their positions, 34 reducing their positions, and 15 closing their positions.
60% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 15
53% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 34
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
32% more capital invested
Capital invested by funds: $1.04B → $1.37B (+$332M)
8% more funds holding
Funds holding: 114 → 123 (+9)
40% less call options, than puts
Call options by funds: $2.5M | Put options by funds: $4.19M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$34.1M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$19.5M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$18.8M |
| 4 |
BlackRock
New York
|
+$18.4M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$15.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$33.6M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$30.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$26M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$16.5M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$14.6M |
BOLD Hedge Fund Activity: Q2 2018 in Review
123 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Audentes Therapeutics, Inc (BOLD) for Q2 2018, worth a combined $1.37B — up 32% from $1.04B a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new BOLD positions and 15 closed out — a net gain of 9 holders — while 52 added to existing stakes and 34 trimmed.
The largest buyer was Redmile Group, adding an estimated $34.1M. The largest seller was OrbiMed, cutting an estimated $33.6M.
- 123 institutional investors held Audentes Therapeutics, Inc (BOLD) as of Q2 2018, up from 114 in Q1 2018.
- Funds reported $1.37B of Audentes Therapeutics, Inc stock for Q2 2018, up 32% quarter-over-quarter.
- 24 funds opened new Audentes Therapeutics, Inc positions in Q2 2018 and 15 closed out, a net change of +9 holders.
- The largest Audentes Therapeutics, Inc buyer in Q2 2018 was Redmile Group, an estimated $34.1M added.
- The largest Audentes Therapeutics, Inc seller in Q2 2018 was OrbiMed, an estimated $33.6M sold.
Based on aggregated 13F filings for Q2 2018.